This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: Fujifilm Corporation. Active years: 2015-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2018
Title: Atsushi Tsuji: Innovator in Monoclonal Antibody Development
Introduction
Atsushi Tsuji is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, Tsuji's work focuses on enhancing the specificity and effectiveness of biomarkers used in cancer detection and diagnosis.
Latest Patents
Tsuji's latest patents include innovative monoclonal antibodies targeting necrosis markers. One of his notable inventions is a monoclonal antibody against the necrosis marker PRDX4. This invention addresses the problem of providing a highly specific biomarker for the detection and diagnosis of various lesions related to carcinomas and necrosis. The antibody consists of an amino acid sequence that can undergo substitutions, deletions, or insertions while maintaining its functional properties.
Another significant patent is for a monoclonal antibody against the necrosis marker ERP29. Similar to his previous work, this invention aims to provide a specific biomarker for effective detection and diagnosis of lesions associated with carcinomas and necrosis. The antibody also consists of an amino acid sequence that allows for variations while retaining its essential functions.
Career Highlights
Atsushi Tsuji is currently associated with Fujifilm Corporation, where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential applications in medical diagnostics and cancer research. Tsuji's dedication to advancing the understanding of necrosis markers has positioned him as a key figure in his field.
Collaborations
Throughout his career, Tsuji has collaborated with notable colleagues, including Sumio Sugano and Yukari Kanzaki. These partnerships have contributed to the development of his groundbreaking patents and have fostered a collaborative environment for innovation.
Conclusion
Atsushi Tsuji's contributions to the field of monoclonal antibodies represent a significant advancement in cancer diagnostics. His innovative work continues to pave the way for more effective detection methods, ultimately benefiting the medical community and patients alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile